Figure 1:



Source
Vaccine
Cases
Total Vaccinations Administered
Proportion (95% CI)
Not clearly adjudicated
Netherlands Pharmacovigilance Centre ChAdOx1-S 3 300000 10.00 (2.06, 29.22)
UK MHRA ChAdOx1-S 30 3.2e+06 9.50 (6.41, 13.56)
Danish Medicines Agency ChAdOx1-S 6 149675 40.09 (14.71, 87.25)
Australian Health Department ChAdOx1-S+mRNA 19 183006 103.82 (62.51, 162.13)
Institute of Public Health of Chile CoronaVac (Sinovac) 49 3.4e+06 14.50 (10.73, 19.17)
Health Ministry, Mexico mRNA 5 44000 113.64 (36.90, 265.17)
Minister of State for Health, Singapore mRNA 4 155000 25.81 (7.03, 66.07)
Health minister, Poland mRNA 5 250000 20.00 (6.49, 46.67)
Health Ministry, Israel mRNA 321 8.5e+06 37.76 (33.75, 42.13)
Minister, Japan mRNA 17 107558 158.05 (92.08, 253.05)
Norwegian Medicines Agency mRNA 8 412576 19.39 (8.37, 38.21)
Netherlands Pharmacovigilance Centre mRNA 12 1.4e+06 8.57 (4.43, 14.97)
Swissmedic and EOC reference centre mRNA 8 962046 8.32 (3.59, 16.39)
UK MHRA mRNA 130 6.3e+06 20.65 (17.26, 24.53)
Institute of Public Health of Chile mRNA 11 292534 37.60 (18.77, 67.28)
Danish Medicines Agency mRNA 63 707543 89.04 (68.42, 113.92)
Summary 33.51 (17.24, 65.14)
Adjudicated
Union health Ministry, India ChAdOx1-S 2 6.3e+06 0.32 (0.04, 1.14)
UK MHRA ChAdOx1-S 5 3.2e+06 1.58 (0.51, 3.69)
Danish Medicines Agency ChAdOx1-S 5 149675 33.41 (10.85, 77.96)
Australian Health Department ChAdOx1-S+mRNA 1 183006 5.46 (0.14, 30.44)
Institute of Public Health of Chile CoronaVac (Sinovac) 12 3.4e+06 3.55 (1.84, 6.20)
NCT04505722, multinational J&J 0 21895 0.00 (0.00, 168.47)
NCT04530396, Russia Sputnik V 1 31465 31.78 (0.80, 177.06)
CDC, USA mRNA 66 1.8e+07 3.77 (2.91, 4.79)
MGB (Boston), USA mRNA 16 64900 246.53 (140.92, 400.32)
PHAC, Canada mRNA 50 2.3e+06 22.17 (16.46, 29.23)
NCT04470427, USA mRNA 1 29892 33.45 (0.85, 186.38)
NCT04368728, multinational mRNA 0 37416 0.00 (0.00, 98.59)
UK MHRA mRNA 18 6.3e+06 2.86 (1.69, 4.52)
Institute of Public Health of Chile mRNA 6 292534 20.51 (7.53, 44.64)
Danish Medicines Agency mRNA 25 707543 35.33 (22.87, 52.16)
Summary 7.91 (4.02, 15.59)
Test for interaction, p<0.0001
0 100 500 1000
Incidence per million doses

Figure 2




A
Author
2nd Doses Administered
2nd Dose Anaphylaxis
Proportion (95% CI)
Tuong et al 15 2 13.33 (1.66, 40.46)
Krantz et al 4 0 0.00 (0.00, 60.24)
Rassmussen et al 30 0 0.00 (0.00, 11.57)
Krantz et al 162 3 1.85 (0.38, 5.32)
Kessel et al 18 0 0.00 (0.00, 18.53)
Kelso et al 3 0 0.00 (0.00, 70.76)
Mustafa et al 2 0 0.00 (0.00, 84.19)
Vanijcharoenkarn et al 73 0 0.00 (0.00, 4.93)
Robinson et al 860 0 0.00 (0.00, 0.43)
Eastman et al 53 0 0.00 (0.00, 6.72)
Park et al 1 0 0.00 (0.00, 97.50)
Arroliga et al 6 0 0.00 (0.00, 45.93)
Loli-Ausejo et al 10 0 0.00 (0.00, 30.85)
Pitlick et al 44 0 0.00 (0.00, 8.04)
Yacoub et al 8 0 0.00 (0.00, 36.94)
Shavit et al 6 0 0.00 (0.00, 45.93)
Kohli-Pamnani et al 16 0 0.00 (0.00, 20.59)
Inoue et al 2 0 0.00 (0.00, 84.19)
Warren et al 22 1 4.55 (0.12, 22.84)
Carpenter et al 1 0 0.00 (0.00, 97.50)
Kaplan et al 30 0 0.00 (0.00, 11.57)
Overall (I² = 0.31%) 1366 6 (1360 successes) 0.16 (0.01, 2.94)
0
50
100
Percentage (%)
B
Author
2nd Doses Administered
2nd Doses with Non-Severe Symptoms
Proportion (95% CI)
Tuong et al 15 6 40.00 (16.34, 67.71)
Krantz et al 4 0 0.00 (0.00, 60.24)
Rassmussen et al 30 0 0.00 (0.00, 11.57)
Krantz et al 162 32 19.75 (13.92, 26.73)
Kessel et al 18 4 22.22 (6.41, 47.64)
Kelso et al 3 0 0.00 (0.00, 70.76)
Mustafa et al 2 0 0.00 (0.00, 84.19)
Vanijcharoenkarn et al 73 5 6.85 (2.26, 15.26)
Robinson et al 860 146 16.98 (14.53, 19.66)
Eastman et al 53 17 32.08 (19.92, 46.32)
Park et al 1 0 0.00 (0.00, 97.50)
Arroliga et al 6 0 0.00 (0.00, 45.93)
Loli-Ausejo et al 10 5 50.00 (18.71, 81.29)
Pitlick et al 44 7 15.91 (6.64, 30.07)
Yacoub et al 8 3 37.50 (8.52, 75.51)
Shavit et al 6 3 50.00 (11.81, 88.19)
Kohli-Pamnani et al 16 3 18.75 (4.05, 45.65)
Inoue et al 2 0 0.00 (0.00, 84.19)
Warren et al 22 0 0.00 (0.00, 15.44)
Carpenter et al 1 0 0.00 (0.00, 97.50)
Kaplan et al 30 1 3.33 (0.08, 17.22)
Overall (I² = 27.02%) 1366 232 (1134 successes) 13.65 (7.76, 22.90)
0
50
100
Percentage (%)
C
Author
Persons with Anaphylaxis To 1st Dose Who Were Revaccinated
Repeat Anaphylaxis Cases
Proportion (95% CI)
Tuong et al 1 0 0.00 (0.00, 97.50)
Krantz et al 4 0 0.00 (0.00, 60.24)
Rassmussen et al 4 0 0.00 (0.00, 60.24)
Krantz et al * 22 3 13.64 (2.91, 34.91)
Kessel et al 7 0 0.00 (0.00, 40.96)
Kelso et al 3 0 0.00 (0.00, 70.76)
Vanijcharoenkarn et al 4 0 0.00 (0.00, 60.24)
Robinson et al 3 0 0.00 (0.00, 70.76)
Eastman et al 2 0 0.00 (0.00, 84.19)
Park et al 1 0 0.00 (0.00, 97.50)
Pitlick et al 4 0 0.00 (0.00, 60.24)
Kohli-Pamnani et al 1 0 0.00 (0.00, 97.50)
Warren et al 17 1 5.88 (0.15, 28.69)
Kaplan et al 5 0 0.00 (0.00, 52.18)
Overall (I²=0.51%) 78 4 (74 successes) 4.94 (0.93, 22.28)
0
50
100
Percentage (%)

Figure 3

A


Study TP FP FN TN Sensitivity Sensitivity (95%CrI) SeWgt(%) Specificity Specificity (95%CrI) SpWgt(%)
Overall 5 27 88 458 0.03[0.00 - 0.08] 100.00 0.98[0.95 - 1.00] 100.00
I²(Sensitivity) = 0.03 [0.00-0.08]
I²(Specificity) = 0.03 [0.00-0.09]
I²(Bivariate) = 0.02 [0.00-0.06]
0.0 0.5 1.0
0.0 0.5 1.0

B




Study TP FP FN TN Sensitivity Sensitivity (95%CrI) SeWgt(%) Specificity Specificity (95%CrI) SpWgt(%)
AlMuhizi et al (PB) 0 0 0 1 0.00 [0.00 - 0.00] 4.94 1.00 [0.03 - 1.00] 3.89
Cahil and Kan (PB) 0 0 0 2 0.00 [0.00 - 0.00] 4.81 1.00 [0.16 - 1.00] 4.80
Kelso et al (PB) 0 0 1 2 0.00 [0.00 - 0.98] 4.38 1.00 [0.16 - 1.00] 4.57
Kessel et al (PB) 0 0 3 12 0.00 [0.00 - 0.71] 6.93 1.00 [0.74 - 1.00] 5.77
Kohli-Pamnani et al (M) 0 3 0 13 0.00 [0.00 - 0.00] 5.61 0.81 [0.54 - 0.96] 7.35
Kohli-Pamnani et al (PB) 0 1 0 15 0.00 [0.00 - 0.00] 5.32 0.94 [0.70 - 1.00] 7.07
Loli-Ausejo et al (PB) 0 0 3 3 0.00 [0.00 - 0.71] 7.00 1.00 [0.29 - 1.00] 4.60
Van Meerbeke et al (M) 0 0 0 4 0.00 [0.00 - 0.00] 4.78 1.00 [0.40 - 1.00] 5.27
Van Meerbeke et al (PB) 0 0 0 4 0.00 [0.00 - 0.00] 4.76 1.00 [0.40 - 1.00] 5.27
Mustafa et al (M) 0 2 0 0 0.00 [0.00 - 0.00] 5.99 0.00 [0.00 - 0.84] 6.67
Park et al (PB) 0 0 0 1 0.00 [0.00 - 0.00] 4.87 1.00 [0.03 - 1.00] 3.94
Pitlick et al (PB) 0 0 2 5 0.00 [0.00 - 0.84] 5.94 1.00 [0.48 - 1.00] 5.13
Pitlick et al (M) 0 0 0 2 0.00 [0.00 - 0.00] 4.86 1.00 [0.16 - 1.00] 4.59
Rassmussen et al (PB) 0 0 0 16 0.00 [0.00 - 0.00] 4.55 1.00 [0.79 - 1.00] 6.01
Tuong et al (PB) 0 1 1 2 0.00 [0.00 - 0.98] 5.32 0.67 [0.09 - 0.99] 6.79
Tuong et al (M) 2 1 1 3 0.67 [0.09 - 0.99] 9.48 0.75 [0.19 - 0.99] 6.95
Warren et al (PB) 1 0 0 5 1.00 [0.03 - 1.00] 5.71 1.00 [0.48 - 1.00] 5.89
Warren et al (M) 0 0 0 5 0.00 [0.00 - 0.00] 4.75 1.00 [0.48 - 1.00] 5.44
Overall 3 8 11 95 0.20[0.01 - 0.52] 100.00 0.97[0.90 - 1.00] 100.00
I²(Sensitivity) = 0.13 [0.00-0.28]
I²(Specificity) = 0.02 [0.00-0.09]
I²(Bivariate) = 0.03 [0.00-0.09]
0.0 0.5 1.0
0.0 0.5 1.0

Figure 4

A




I^2(Sensitivity) = 0.02 [0.00-0.05]

I^2(Specificity) = 0.00 [0.00-0.01]

I^2(Bivariate) = 0.00 [0.00-0.00]

B



I^2(Sensitivity) = 0.02 [0.00-0.07]

I^2(Specificity) = 0.02 [0.00-0.05]

I^2(Bivariate) = 0.01 [0.00-0.03]